Vivani Medical, Inc. (VANI) - 10-K Summary
Business Context and Reporting Period
Company: Vivani Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Vivani is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. The technology aims to address medication non-adherence in chronic diseases, specifically focusing on GLP-1 receptor agonists for obesity and type 2 diabetes. The company operates two segments: the Biopharm Division (primary focus) and the Neurostimulation Division (Cortigent, Inc., a wholly-owned subsidiary).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(26,609) | $(23,486) |
| Operating Expenses | $27,556 | $24,677 |
| Research & Development | $18,126 | $15,745 |
| General & Administrative | $9,430 | $8,932 |
| Cash Used in Operating Activities | $(24,320) | $(20,786) |
| Cash Provided by Financing Activities | $23,274 | $19,054 |
| Cash and Cash Equivalents (Ending) | $16,232 | $18,352 |
| Total Assets | $39,393 | $41,561 |
| Accumulated Deficit | $(148,533) | $(121,924) |
Note: The company has no products approved for commercial sale and has not generated revenue to date.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $3.1 million (13%) to $26.6 million in 2025, driven primarily by higher clinical trial and development expenses in the Biopharm Division and increased professional services.
- R&D Expense Growth: R&D expenses rose 15% to $18.1 million, reflecting the advancement of clinical programs, specifically the LIBERATE-1 trial.
- Capital Raising: The company raised approximately $23.3 million in financing activities during 2025 through registered direct offerings and private sales transactions to fund operations.
- Segment Performance: The Biopharm Division incurred a net loss of $24.1 million, while the Neurostimulation Division (Cortigent) incurred a net loss of $2.5 million.
Guidance, Outlook, and Management Commentary
Clinical Progress:
- LIBERATE-1 Trial: Successfully completed the first-in-human clinical trial (LIBERATE-1) for NPM-115 (exenatide implant) in Australia in 2025. Top-line data released in August 2025 demonstrated a positive safety and tolerability profile and encouraging performance data.
- NPM-139 (Semaglutide): Based on LIBERATE-1 results and positive preclinical data showing ~20% weight loss maintained for over 6 months, the company prioritized NPM-139. A Phase 1 clinical study is expected to initiate in mid-2026.
- NPM-133 (Semaglutide): Development for type 2 diabetes is ongoing, with potential for once-yearly dosing.
Strategic Transactions:
- Cortigent Spin-off: The company is pursuing a spin-off of its Neurostimulation Division (Cortigent) via a Form 10 registration statement filed in May 2025. A record date was set in September 2025 but withdrawn in October due to U.S. federal government shutdown delays. An IPO via Form S-1 is also being considered.
- Okava Partnership: Expanded collaboration with Okava Pharmaceuticals to include dogs in the development of OKV-119, adding $5 million in regulatory milestone payments.
Liquidity and Outlook:
- The company estimates current cash will fund operations into mid-2027.
- Additional capital will be required to pursue business objectives; failure to obtain funding could force delays or termination of development programs.
- Risks: Significant risks include the uncertainty of clinical trial outcomes, regulatory approval (FDA), reliance on third-party manufacturers, and the need for substantial additional financing.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to raise additional capital before mid-2027, given the recurring operating losses and lack of revenue.
- Cortigent Transaction Status: Monitor the progress of the Cortigent spin-off or IPO, as delays or failure to complete could impact stockholder value and the company's balance sheet.
- Regulatory Pathway: Confirm the FDA's acceptance of the 505(b)(2) regulatory pathway for NPM-139, which relies on data from approved semaglutide products (Wegovy/Ozempic).
- Clinical Trial Timelines: Track the initiation of the Phase 1 study for NPM-139 in mid-2026 and the subsequent Phase 2 preparations.
- Legal Contingencies: Review the status of pending litigation, including the appeal against the Paris Commercial Court judgment regarding the Pixium Vision MOU termination and the Oppenheimer breach of contract claim.